The Viking Therapeutics story
What drives Viking Therapeutics, what its price assumes and what could change the story, written from its own filings.
- Maintenance results extend the case. In September 2026, Viking reported up to 97% of weight loss maintained with every other week dosing and up to 90% with monthly dosing for three months.
- Oral development moves forward. Viking expects oral VK2735 Phase 3 trials to begin in the fourth quarter of 2026, following up to 12.2% mean weight loss after 13 weeks in Phase 2.
- Funding remains central. Cash, cash equivalents and short-term investments fell to $502 million at June 2026 from $706 million at December 2025, and Viking entered an equity underwriting agreement in September 2026.
